MK-3475A-D77
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- NCT05722015 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on MK-3475A-D77 (pembrolizumab formulated with berahyaluronidase alfa, pembrolizumab and 7 more in Metastatic Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MK-3475A-D77 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 1 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab Formulated with Berahyaluronidase Alfa; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel; Nab-paclitaxel; Pembrolizumab; Filgrastim; Pegylated filgrastim
- Arms
- Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy · Experimental
- Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy · Active comparator
- Enrollment
- 377
- Primary outcomes
- Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose
- Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Feb 14, 2023
- Primary completion
- Jul 12, 2024
- Results posted
- Yes
- Registry record
- NCT05722015 · updated Aug 26, 2026
Publications
linked from the registry- Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Csoszi T, Sendur MAN, Martins J, Calles Blanco A, Wang CC, Wang M, Ramirez Fallas RAL, Yoshioka H, Nair S, Song X, Deng X, Lala M, Eiras R, Takahashi T. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025 Jul;36(7):775-785. doi: 10.1016/j.annonc.2025.03.012. Epub 2025 Mar 27. PubMed 40157574